Back to search results

Observational Study on Methamphetamine Cue-reactivity

This study is looking at how your brain reacts to things that remind you of methamphetamine (meth) and how that changes over time if you stop using meth. Researchers want to find a way to measure these brain reactions, especially how they might differ between men who have sex with men (MSM) and other men. You could join if you are a man between 18 and 60 years old, have a diagnosis of Methamphetamine Use Disorder, and are either currently using meth or have been abstinent for a certain period. The study will measure changes in your brain's electrical activity (called LPP Amplitude) after about 2 weeks and 3 months of not using meth. This is an observational study, meaning researchers will be watching and learning, not giving a new treatment. The study aims to enroll 88 participants, but the current status of recruitment is unclear.

Study design
This is an observational study involving 88 male participants. It is not testing a new treatment but rather observing brain responses.
What's involved
You will be asked to complete cognitive tasks and your brain's electrical activity will be measured at approximately 2 weeks and 3 months of abstinence.
Compensation
Not stated in the trial record.
Follow-up
Your brain's electrical activity will be measured at approximately 2 weeks and 3 months of abstinence.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07086014

Methamphetamine Cue-reactivity

Recruiting
Not specifiedAges 18–60Observational
Icahn School of Medicine at Mount Sinai
~88 participants
Updated 2025-07-25 on ClinicalTrials.gov
What's tested:Cognitive Reappraisal

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in EEG-derived late positive potential (LPP) Amplitude
Measured over at approx. 2 weeks and 3 months abstinence

Conditions

Methamphetamine Use Disorder

Explore related trials

Amphetamine-induced organic mental disorder

NCT07086014

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Icahn School of Medicine at Mount Sinai

    New York, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Muhammad A Parvaz, PhD · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai

Who to contact

Muhammad A Parvaz
[email protected]
212-241-3638
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ability to understand and give informed consent
Identify as either MSM or non-MSM
Males; Age 18-60
DSM-5 Diagnosis of MUD (Methamphetamine Use Disorder)
Have appropriate abstinence duration \[i.e., current Methamphetamine users (MA): 2 weeks (range: 1-3 weeks); MA-abstinent: 3 months (range: 2-4 months)\]
Treatment-seeking MUD must be in a treatment facility for substance use disorder, with MA as the primary drug (at the first visit)
Treatment-seeking MUD must be abstinent from MA use for approximately 2 weeks (range: 1-3 weeks) at enrollment.

What this trial measures

  • Change in EEG-derived late positive potential (LPP) Amplitudeat approx. 2 weeks and 3 months abstinence

    Change in amplitude (or incubation of) the EEG-derived late positive potential (LPP) - an objective neurophysiological marker of drug cue-reactivity - occurs 400 msec after the onset of a drug-related cue. The LPP amplitude has also shown to predict self-reported craving, simulated drug-seeking behavior and relapse, highlighting the clinical utility of this objective metric of cue-reactivity.